Research on their expression and role in cancer pathogenesis reveals that in the majority of studies the two receptors are downregulated in cancerous tissues; their downregulation and, in particular, that of REV-ERBα are often associated with increased cell proliferation in cell lines, and the use of synthetic agonists seems to restore the cell viability in certain cases [31]. The gene discussed is NR1D1; the disease is cancer.